Biopharma News

Agenus and Merck work together to advance immune-oncology programs.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Novartis receives FDA breakthrough therapy designation for Bexsero, a meningitis B vaccine.

ThioBridge linker technology to attach different payloads to a range of antibodies

uniQure appoints a new COO and vice president, Medical affairs.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.

New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.

Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.

Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.

Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.

Baxter announces plans to split into two independent companies by mid-2015.

XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.

Cobra Biologics and BioCancell announce an agreement to manufacture BioCancell's BC-821 cancer drug.

Novartis calls for more research to understand and find treatments for rare disease.

Debiopharm acquires Affinium's clinical and preclinical assets and its technology platform.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

Teva announced an agreement to acquire NuPathe and its migraine treatment patch.

The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.

J&J's diagnostics business goes to global asset manager, The Carlyle Group.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.